Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Delivery
- Pharmaceuticals
- Cannabis
- Disease
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27852
Licensor's most advanced product in development using RapidMistâ„¢ is Generex Oral-lynâ„¢, an insulin spray product for the treatment of diabetes mellitus.
IPSCIO Record ID: 305318
The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.
Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.
Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.
The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.
Licensor’s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.
With concern growing over vaping and the numerous incidents now being reported, Licensee’s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles. Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.
IPSCIO Record ID: 4186
The Licensee will bear all costs associated with such use, but the Company will retain ownership of any improvements to its buccal drug delivery technologies.
IPSCIO Record ID: 328330
United States Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule
Licensed Technology shall mean the Licensor Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole ingredient, the Designated Compound delivered by means of the Licensed Process.
